CompletedInterventionalPhase 2Phase 3Last updated May 22, 2024

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase II/III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Active Ankylosing Spondylitis

Overview

ClinicalTrials.gov ID: NCT04840485
Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY
Brief Summary: The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Jun 9, 2021Actual
Primary Completion Date: Nov 3, 2023Actual
Completion Date: Feb 28, 2024Actual

Study Record Dates

First Submitted: Apr 7, 2021
First Submitted that Met QC Criteria: Apr 7, 2021
First Posted: Apr 12, 2021Actual
Last Update Submitted that Met QC Criteria: May 21, 2024
Last Update Posted: May 22, 2024Actual
Last Verified: May 2024

NCT06860750Recruiting

A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis

NCT04481139Completed

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis

NCT06640257Active, not recruiting

A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

NCT05055934Completed

Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis

NCT03704428Completed

Safety, Tolerability and PK of SHR1314 in axSpA

NCT05324631Unknown status

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis